Linda Llewelyn - Jul 1, 2021 Form 4 Insider Report for Health Catalyst, Inc. (HCAT)

Role: Chief People Officer
Signature: /s/ Daniel Orenstein, as Attorney-in-Fact
Stock symbol: HCAT
Transactions as of: Jul 1, 2021
Transactions value $: -$182,117
Form type: 4
Date filed: 7/6/2021, 09:07 PM
Previous filing: Jun 7, 2021
Next filing: Aug 4, 2021

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	HCAT	Common Stock	Options Exercise	$13K	+1.1K	+3.05%	$11.78	37.2K	Jul 1, 2021	Direct
transaction	HCAT	Common Stock	Options Exercise	$22.1K	+2.05K	+5.51%	$10.80	39.3K	Jul 1, 2021	Direct
transaction	HCAT	Common Stock	Sale	-$150K	-2.7K	-6.86%	$55.75	36.7K	Jul 1, 2021	Direct	F1, F2
transaction	HCAT	Common Stock	Sale	-$31.7K	-561	-1.53%	$56.43	36.1K	Jul 1, 2021	Direct	F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	HCAT	Stock Option (Right to Buy)	Options Exercise	-$13K	-1.1K	-8.12%	$11.78	12.5K	Jul 1, 2021	Common Stock	1.1K	$11.78	Direct	F4
transaction	HCAT	Stock Option (Right to Buy)	Options Exercise	-$22.1K	-2.05K	-6.19%	$10.80	31K	Jul 1, 2021	Common Stock	2.05K	$10.80	Direct	F5

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The sale reported on this Form 4 was made pursuant to a written trading plan adopted by the Reporting Person on December 9, 2020, in accordance with Rule 10b5-1.
F2	Represents the weighted average sale price of the shares sold ranging from $55.34 to $56.27 per share, inclusive.
F3	Represents the weighted average sale price of the shares sold ranging from $56.37 to $56.54 per share, inclusive. The Reporting Person will provide, upon request by the Issuer, a security holder of the Issuer, or the staff of the Securities and Exchange Commission, full information regarding the number of shares sold at each separate price within the range set forth in this footnote and footnote 2.
F4	25% of the 17,954 shares underlying the options vested in an annual installment on January 24, 2019 and the remaining balance vested or will vest in equal monthly installments until the option vests in full on January 24, 2022.
F5	25% of the 59,351 shares underlying the options vested in an annual installment on September 25, 2019 and the remaining balance vested or will vest in equal monthly installments until the option vests in full on September 25, 2022.